| In This Newsletter |
HealthEconomics.Com: We Curate Content So You Don’t Have To. Are you a Consulting, Conference, or Publication company? Let us help you get the word out to 15,500 HEOR, Pricing, and Market Access professionals.
Looking for employment or recruiting? Check out our Posted Jobs, Other Jobs, and Job Search Tips.
In this issue:
- News: CER impact on MCOs and pharma, changing drug codes affect reimbursement, employers changing co-pays to value-based, and report on pricing strategy.
- Spotlight Feature 1 is Xcenda’s well-respected and tested Outcomes Analyzers, a flexible tool for Payers, Physician Groups, and Employers to use their own medical/pharmacy claims data, and compare to national figures. Identifies targets for interventions, and generates local evidence.
- Spotlight Feature 2 is a relevant, must-attend conference by CBI to help your product gain market share and attain reimbursement: “3rd Annual Product Launch and Market Access Congress”, July 19-20, 2012, Philadelphia, PA.
- Clueless about ACOs or developing a strategy for them? Our Conference of the Week is ExL’s “Accountable Care Organizations Emerging Models: Financing, Assembling, and Developing a Quality of Care for Successful ACO Executioion”, July 23-25, 2012, Baltimore, MD.
- Need help driving ISPOR attendees to your booth, symposia, or presentation? HealthEconomics.Com is tweeting live from ISPOR on many topics. Contact us for options.
- Our Job of the Week is Research Scientist - Health Economics with United BioSource Corp. in Lexington, MA..
- View Resources on Adherence, Market Access/Pricing, and Trends. Additions? Click here.
- New Jobs just posted include Health Economics Manager in UK.
- Most complete Jobs, Conferences, Webinars, White Papers, and Reports list anywhere. Need to add one? Click here.
Need better exposure for your company? Use the HealthEconomics.Com Partnership program to reach 15,500 HEOR professionals around the world. Options for every budget. Contact us.
|
|
| Industry News |
Looking at CER from the MCO Perspective. This JMCP paper describes health reform on MCOs and past/future use of CER data. (Source: AMCP.org)
Looking at CER from the Pharmaceutical Industry Perspective. This JMCP paper looks at positive and negative impact of CER on pharma in terms of information access, communication, policies, and innovation. (Source: AMCP.org)
Call for papers: JMCP Specialty Pharmacy Issue (submit by August 31, 2012). This JMCP theme issue will focus on descriptive reports, commentaries, and research that examine the effects of managed care interventions and programs in specialty pharmacy, one of the fastest growth sectors in pharma (Source: JMCP)
Are you keeping up to date on reimbursement drug codes? Learn about the implications, and make sure you have an internal process for changing drug codes and billable unites, particularly for high-cost medications. (Source: Pharmacy Practice News, May 2012, Vol. 39)
New Report: 2012 Benchmarks in Patient Registry Use for Accountable Care. This report provides actionable data from more than 100 healthcare organizations on current and planned use of patient registries and impact on quality, efficiency and cost. (Source: Healthcare Intelligence Network)
How to run a walking meeting. Kaiser Permanente has "Walking Meetings" to increase health. Give it a try. Here's how.
Rising cost of ‘specialty’ drugs prompts employers to limit their use. Washington Post article about how employers that provide their workers with health insurance are struggling with how to manage these costs. (Source: Washington Post, 5/7/12)
What will dominate future pricing and reimbursement strategies? A new report from GBI Research says reference pricing and economic evaluations will dominate future pricing and reimbursement strategies. Provided are key data, information and analysis of the major issues affecting the pricing and reimbursement decisions across the globe. The report also covers issues specific to particular geographies. (Source: businesswirenews.com, 5/8/12)
Is the US healthcare system mired in maximizing reimbursement to the exclusion of patient outcomes? Report from Healthcare Industry Group takes a convergent view across the spectrum of the healthcare sector to better understand the potential impact of PPACA.
... Read All News
|
| Education and Training |
Four decades of health economics through a bibliometric lens. This paper takes a bibliometric tour of the last forty years of health economics using bibliographic “metadata” from EconLit supplemented by citation data from Google Scholar and the authors' topical classifications. Reported is the growth of health economics (they find 33,000 publications since 1969—12,000 more than in the economics of education) and list the 300 most-cited publications broken down by topic. (Source: Health Equity)
Peruse the Educational Resources on HealthEconomics.Com by clicking here.
|
|
|
| Link of the Week |
Should drug co-payments be based on the value that a drug provides?
Some employers are changing co-pays to be based on value provided, particularly for pricier specialty drugs with no generic competition. What are the implications for your reimbursement plan and market share? (Source: NPR.org, 5/8/12)
Reserve "Link of the Week". Contact Us.
|
|
|
|
|
|
|
|
|
|
|
